Advertisement

Topics

Antoxerene Closes $10 Million Deal with Juvenescence to Develop Small Molecule Drugs for Diseases of Aging

10:50 EDT 12 Jul 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Antoxerene, Inc., a portfolio company of Ichor Therapeutics, Inc., focused on small molecule drug discovery for pathways of aging, announced today the launch of a joint venture with Juvenescence Limited. The joint venture...

Other Sources for this Article

Juvenescence
Stephanie Martens
stephanie.martens@ichortherapeutics.com
+1 315 677-8400

NEXT ARTICLE

More From BioPortfolio on "Antoxerene Closes $10 Million Deal with Juvenescence to Develop Small Molecule Drugs for Diseases of Aging"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...